While glomerular IgM deposition occurs in a variety of glomerular diseases the mechanism of deposition and its clinical significance remain controversial. Some have theorized IgM becomes passively trapped in areas of glomerulosclerosis. However, recent studies found that IgM specifically binds damaged glomeruli. Therefore, we tested whether natural IgM binds to neoepitopes exposed after insults to the glomerulus and exacerbate disease in mice deficient in the complement regulatory protein factor H; a model of non-sclerotic and nonimmune-complex glomerular disease. Immunofluorescence microscopy demonstrated mesangial and capillary loop deposition of IgM while ultrastructural analysis found IgM deposition on endothelial cells and subendothelial areas. Factor H deficient mice lacking B cells were protected from renal damage, as evidenced by milder histologic lesions on light and electron microscopy. IgM, but not IgG, from wild-type mice bound to cultured murine mesangial cells. Furthermore, injection of purified IgM into mice lacking B cells bound within the glomeruli and induced proteinuria. A monoclonal natural IgM recognizing phospholipids also bound to glomeruli in vivo and induced albuminuria. Thus, our results indicate specific IgM antibodies bind to glomerular epitopes and that IgM contributes to the progression of glomerular damage in this mouse model of non-sclerotic glomerular disease.
INTRODUCTION
Various glomerular diseases demonstrate IgM on biopsy; however, the clinical significance of glomerular IgM remains controversial. Glomerular IgM deposition is described in diseases of widely ranging etiology such as focal segmental glomerulosclerosis (FSGS), 1 minimal change disease, 2 mesangioproliferative glomerulonephritis, 3 hypertensive nephrosclerosis, 4 and diabetic nephropathy. 5 A commonly held view is the presence of glomerular IgM represents passive trapping of the large IgM macromolecule within areas of sclerosis. Such a phenomenon would explain glomerular deposition of IgM occurring in this broad array of diseases. However, attributing glomerular IgM deposition to passive trapping does not explain the often seen co-deposition of complement protein C3, nor does it explain the absence of other proteins that are similar in molecular weight to C3 such as IgG. An alternative hypothesis is that IgM binds to specific glomerular epitopes expressed or revealed by various insults. In other words, glomerular IgM and complement activation may represent a common final pathway of injury to the glomerulus after toxic, hemodynamic, metabolic, and immunologic insults.
Several clinical observations support the hypothesis that IgM specifically binds epitopes in injured or stressed glomeruli and exacerbates disease. Studies demonstrate IgM deposition in patients with pure diffuse mesangial hypercellularity in the absence of sclerosis. 6 Furthermore, IgM is not uniformly seen in globally sclerosed glomeruli. Observational studies of patients with nephrotic syndrome and IgM deposition indicate it is a poor prognostic factor clinically. The presence of IgM is associated with steroid unresponsiveness 7, 8 and a poor response to standard immunosuppression. 9 IgM deposition in nephrotic syndrome is also associated with the development of impaired renal function 10 and is predictive of progression to end stage renal disease. 7, 9 Taken together, these observations suggest glomerular IgM is associated with more severe disease in patients with nephrotic syndrome.
Natural antibody is a class of immunoglobulin generated even without exposure to a specific target antigen. Recent research has identified several important functions of natural IgM antibody. Natural IgM binds self epitopes generated during ischemia, [11] [12] [13] aids in the removal of injured tissue, 14 and is an activator of the complement system. Thus, natural IgM appears to have both beneficial and maladaptive functions. Natural IgM helps to clear damaged and apoptotic cells and protects the individual from infection. However, natural IgM can also contribute to tissue injury through activation of the complement system and generation of tissue inflammation.
We recently demonstrated IgM contributes to glomerular disease progression in an experimental model of chemically induced FSGS. 15 In that model, the depletion of B cells reduced glomerular IgM as well as deposition of complement proteins. The decrease in glomerular IgM corresponded with an attenuated degree of albuminuria and glomerulosclerosis. These findings support the concept that IgM binds to the damaged glomerulus, activates complement, and causes further glomerular injury. An analysis of human biopsy tissue from patients with FSGS similarly demonstrated glomerular IgM and the complement protein C3d, an activation fragment of complement. These findings indicate IgM activates complement within the glomerulus and argues against the theory that circulating IgM and C3 become passively trapped in sclerotic glomeruli.
Based on our previous work we hypothesize IgM binds neo-epitopes generated or exposed after non-scarring insults to the glomerulus and is a generalized response to glomerular injury. In order to assess IgM involvement in a non-sclerotic model of glomerular injury we utilized mice with a targeted deletion of the gene for the complement regulatory protein factor H (fH −/− mice). Deletion of factor H results in uncontrolled alternative complement pathway activation and glomerular injury. However, the glomerular disease is not associated with glomerulosclerosis. To test the functional importance of IgM in this model of glomerular disease we crossed fH −/− mice with μMT mice, generating fH −/− /μMT double knockout mice. The μMT mice carry a targeted disruption of the gene for the IgM μ chain. 16 Although a small population of mature B cells in these mice can produce IgG, IgA, and IgE, the mice do not produce detectable IgM. [16] [17] [18] We also injected wild-type, μMT, and fH −/− /μMT mice with IgM from wild-type mice or monoclonal natural IgM clones to determine whether IgM binds glomerular epitopes in these different strains.
RESULTS

IgM deposition is progressive in factor H deficient mice
Kidney sections from fH −/− mice at three, six, and nine months of age were assessed for glomerular deposition of IgM by immunofluorescence. Glomeruli of fH −/− mice demonstrated consistent IgM deposition occurring in a progressive fashion as the mice aged (representative glomeruli are shown in Figure 1a and b). Further localization of the IgM deposits demonstrated a change over time in mice with fH −/− mediated glomerulonephritis. In the fH −/− strain the areas of glomerular IgM deposition appear mesangial in distribution at three months of age (Figure 1a ). At this time point the IgM deposits are distinct from glomerular C3 (Figure 1e ). However, as the mice age and as disease worsens IgM deposition expands from the mesangium into glomerular capillary loops (Figure 1b and f) . In contrast to IgM, glomerular IgG deposition in the fH −/− strain was negative. Figure 2e shows a representative tissue section from a nine month-old fH −/− mouse demonstrating negative staining by immunofluorescence for IgG. Wild-type mice developed minimal IgM deposition over time. Assessment of fH −/− /μMT kidney sections confirmed there was no glomerular IgM present in this strain.
Complement components are deposited within the glomeruli of factor H deficient mice
Activated C3 fragments were present along the glomerular capillary loops of fH −/− mice, as previously described. 19 Glomerular C3 deposition remained constant throughout the capillary loops at both time points (Figure 1c and d) . Glomerular deposition of the complement components C4 and C1q were seen in 9 month-old fH −/− animals ( Figure 2a and c), indicating that glomerular IgM deposits activate the classical pathway in fH −/− mice.
Neither C4 nor C1q were detected in fH −/− /μMT kidney sections from 9 month-old animals ( Figure 2b and d) .
IgM binds to injured glomerular capillary loops
Kidney sections from nine month-old fH −/− mice were analyzed by immunofluorescence with an antibody directed against synaptopodin (a podocyte marker) and IgM, shown in Figure 3c , which demonstrates separate regions of synaptopodin and IgM staining. This is also seen on cross-section of the glomerular capillary loops, as shown in the magnified inset of Figure 3c . Further ultrastructural analysis by immunogold EM demonstrated IgM deposition on endothelial cells and in subendothelial areas in 9 month old fH −/− mice ( Figure  3d ).
IgM, but not IgG, binds mesangial cells in vitro
A murine mesangial cell culture line (MES-13 cell line) was incubated with 10% wild-type mouse serum in PBS at 37°C and analyzed by flow cytometry to determine whether the IgM or IgG in normal mouse serum bound to the cells. As shown in Figure 4 , mesangial cells demonstrated selective binding by IgM (a), but not IgG (b). We assessed a pancreatic endothelial cell line (MS-1) in similar fashion for IgM binding. These endothelial cells did not demonstrate IgM binding by flow cytometry (Figure 4c) . Thus, the binding of IgM in serum appears to be cell type specific. C3 deposition was detected on the mesangial cells that bound IgM when incubated with wild-type serum (Figure 4d ), demonstrating that the complement system is activated on the cell surface.
Polyclonal IgM and specific natural IgM clones bind glomerular epitopes in vitro
Purified polyclonal murine IgM bound to primary culture of murine mesangial cells ( Figure  5a ) and to a murine mesangial cell line (MES-13 cells, Figure 5b ) at 37°C. To characterize the binding of IgM to glomerular epitopes, we screened monoclonal natural IgM clones for their ability to bind to mesangial cells at 37°C. Two of the monoclonal IgM clones tested, C2 and F632, bound to mesangial cells (MES-13) in vitro (Figure 5b) . The five other clones tested did not bind to the mesangial cells (Figure 5c ). We also tested the binding of the monoclonal antibodies to mesangial cells grown in primary culture. C2 and F632 also bound to these mesangial cells, whereas the other IgM clones did not.
Polyclonal IgM and specific natural IgM clones bind glomerular epitopes in vivo
To determine the glomerular binding of IgM in vivo, fH −/− /μMT and μMT mice were injected intravenously with 1 mg of purified polyclonal IgM or 100 μg of monoclonal IgM clones. After 24 hours kidney sections were examined by immunofluorescence microscopy. Glomerular IgM was observed in the kidney sections from fH −/− /μMT mice injected with polyclonal IgM (Figure 6a ) but only a small amount was seen in μMT mice (Figure 6b Some IgM is present in the mesangium of wild-type mice. To confirm that exogenous IgM targets the glomeruli in wild-type mice, polyclonal IgM was labeled with biotin and injected into wild-type mice. After 24 hours the kidneys were harvested and the biotin label was detected in the glomeruli ( Figure 7 ).
Purified polyclonal and monoclonal IgM induce albuminuria in vivo
μMT mice injected with purified IgM developed an increase in albuminuria one day after injection (P < 0.05 by ANOVA for baseline versus day one, Figure 8a At 9 months, evaluation of fH −/− /μMT mice for clinical markers of renal disease demonstrated attenuation of albuminuria compared to age-matched fH −/− mice, although this did not achieve statistical significance ( Figure 11 ). Renal function appeared normal in all of the strains as assessed by serum markers (serum urea nitrogen and creatinine). Wild-type, μMT, fH −/− , and fH −/− /μMT mice had no significant difference in blood urea nitrogen or creatinine values.
DISCUSSION
Despite the presence of IgM in a variety of distinct glomerular diseases, the functional consequences remain a source of debate. In the current study the involvement of IgM in a non-sclerotic and non-immune complex model of glomerular disease was assessed using mice with a targeted genetic deletion of factor H. In addition to supporting the concept that glomerular IgM binding is a specific process, these results may be useful for identifying the glomerular epitopes to which IgM binds. The C2 IgM clone was previously shown to bind to certain phospholipids, including phosphatidylcholine, phosphatidylethanolamine, and cardiolipin, but not to proteins. 20, 21 Natural IgM has also been shown to bind to phospholipids on apoptotic T cells. 22 It is important to note that natural IgM is polyreactive, so it is possible the C2 IgM clone binds to a different epitope in this particular disease model.
Our data suggest progressive glomerular IgM deposition plays an active role in exacerbation of proteinuric glomerular disease. Glomerular damage may expose or generate neo-epitopes. IgM specific for these epitopes then binds within the damaged glomerulus and further contributes to disease progression and albuminuria. IgM binding within the glomerulus in conjunction with the local activation of complement could play a key role in the disease progression from a variety of primary glomerular insults. The detection of glomerular IgM and C3 on kidney biopsies may, therefore, identify an important subset of patients in whom the innate immune system contributes to disease progression. Furthermore, IgM and the complement system could represent novel therapeutic targets for slowing glomerular disease progression.
A limitation to our study is the mild nature of renal injury in the fH −/− mice. Although histologic injury and albuminuria were attenuated in B cell deficient mice, not all of the endpoints achieved significance. We believe the binding of IgM within the glomerulus is a secondary phenomenon and cannot account for all of the renal damage. Thus, in a mild model of glomerular injury the degree of protection will be modest. Interestingly, a previous study demonstrated that the glomerular C3 deposits converted to a mesangial pattern when fH −/− mice were reconstituted with purified factor H. 23 The mesangial C3 deposition that emerged after factor H was restored may have been be due to the presence of mesangial IgM deposits. Based upon our results it is also possible that the efficacy of purified factor H for reversing glomerular disease in this model will be lost once sufficient IgM is deposited in the glomerulus, a concept that we will test in future experiments. Previous studies have shown there is sufficient complement activation in these mice to mediate antibody-mediated glomerular injury. 24 A receptor for IgM was also recently described 25 and it is possible that some of the pathologic effects of glomerular IgM are mediated through the interaction with this receptor and not through complement activation. However, our data demonstrated specific IgM clones bound glomerular cells while other clones did not bind. This suggests these clones are directed to a specific target epitope. If binding were occurring via the Fc receptor for IgM, we would anticipate that all of the monoclonal IgM antibodies would bind. Nevertheless, this model allows us to identify a secondary pathogenic role of IgM in a disease that is generally regarded as not involving immunoglobulin.
Debate remains as to the clinical significance of IgM deposition in glomerular disease. Clinical studies of patients with nephrotic syndrome demonstrate conflicting evidence for the contribution of glomerular IgM to the disease process. Some demonstrated more severe manifestations of nephrotic syndrome in association with glomerular IgM deposition (steroid unresponsiveness, impaired renal function, and progressive disease). [7] [8] [9] [10] However, not all have demonstrated a significant role for IgM in nephrotic syndrome. 26, 27 It is also clear not all patients with glomerular disease develop IgM and complement deposition. However, it may be deposition of IgM and complement identifies a subset of patients in whom these molecular mechanisms are engaged. The current study shows binding of IgM within the glomerulus can be a downstream event occurring secondary to glomerular damage. This may serve as part of the repair process to help remove apoptotic cells but may also result in local tissue damage. Even though the involvement of IgM may occur in a subset of patients with any given glomerular lesion, in aggregate IgM specific for glomerular epitopes may be a common cause of progressive injury across a large number of different glomerular diseases.
Most of the immunosuppressive agents commonly used to treat patients with glomerular disease (such as corticosteroids, cyclophosphamide, and cyclosporine) do not inhibit innate immune factors such as natural antibody generation and the complement system. [28] [29] [30] Furthermore, even though the B-1 cells that generate natural IgM express CD20 they are resistant to depletion with rituximab. 31 Consequently, standard immunosuppressive agents may not be effective at blocking these innate immune mediators' role in disease progression. This may explain the resistance to standard immunosuppressive agents seen in groups of patients with glomerular disease. It may also explain the variability in the degree of steroid responsiveness reported in clinical studies of nephrotic patients with IgM deposition. A better understanding of these disease mechanisms is needed to develop more effective therapeutics. Agents that block these innate immune factors could have the potential to slow glomerular disease progression without unnecessarily impairing adaptive immune functions.
In conclusion, this study indicates a functional role for IgM in the progression of this murine model of non-sclerotic glomerular disease. The applicability of the findings in this study needs to be confirmed in humans. Although, the presence of glomerular IgM and complement proteins in patients with a variety of glomerular diseases suggests a similar process may occur. Glomerular injury may lead to expression of de novo antigens or exposure of hidden antigens for which there is an innate immune response. If so, IgM may be an amplifying mechanism in many forms of glomerular disease after a wide range of triggering insults, including immunologic and non-immunologic injury of the kidney.
MATERIALS AND METHODS
Derivation of fH −/− , μMT, and fH −/− /μMT mice
Experimental cohorts included male wild type, factor H knockout (fH −/− ), and fH −/− /μMT double knockout mice on a C57BL/6 background. Factor H knockout mice were provided by Matthew Pickering and generated as previously described. 19 The μMT mice (Jackson ImmunoResearch, West Grove, PA, strain 002288) and the fH −/− mice were each backcrossed onto a C57BL/6 background for nine generations. The mice were then intercrossed to generate the double knockout fH −/− /μMT −/− mice. Animals were harvested at three to nine months of age. All mice were maintained at the University of Colorado Center for Laboratory Animal Care in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and the Public Health Service Policy on Humane Care and Use of Laboratory Animals.
Albumin, serum urea nitrogen, and creatinine measurements
Urine albumin was determined by ELISA according to manufacturer's instructions (Bethyl Laboratories, Inc, Montgomery, TX). Serum urea nitrogen and serum and urine creatinine were determined by automated analysis with the AlfaWassermann ACE® Clinical Chemistry Analyzer.
Renal histology
Kidney tissue was fixed in formalin, embedded in paraffin, cut into 4 μm sections, and stained with periodic acid-Schiff and Masson's trichrome stain for evaluation by light microscopy. Sections were assessed for the extent of hypercellularity, double contours, and glomerulosclerosis. Histologic analysis was performed by a renal pathologist blinded to study groups. Fifty glomeruli per animal per section were analyzed. The average involvement of glomerular lesions of the 50 glomeruli examined per animal is represented as a single data point in Figure 9 panels e and f.
Additional kidney tissue for electron microscopy was fixed in 2% glutaraldehyde / 2% paraformaldehyde with 0.1 M cacodylic acid and 3% sucrose, embedded in resin, and cut into ultrathin sections. Three animals per group and eight to twelve glomeruli per animal were analyzed by a renal pathologist blinded to study groups.
Immunofluorescence microscopy
Snap-frozen kidney sections (5 μm) were stained with Cy3-conjugated goat antibody against mouse IgM (Jackson ImmunoResearch) or FITC-conjugated goat antibody against mouse C3 (MP Biomedicals) and assessed by immunofluorescence as previously described. 15 Staining with a rabbit antibody against mouse synaptopodin (Sigma, St. Louis, MO) was used to localize podocytes followed with a secondary FITC-conjugated donkey antibody against rabbit IgG (Jackson ImmunoResearch). Appropriate secondary antibodies and isotype controls were obtained from Jackson ImmunoResearch.
High-powered images of 25 glomeruli per animal per section were obtained on an Olympus BX51 microscope. The relative fluorescence units were measured by ImageJ software and image overlays were created in Adobe Photoshop CS3 (San Jose, CA). The measured relative fluorescent units for each glomerulus were normalized by correcting for the background fluorescence on the image. The average value of the normalized relative fluorescent units from the 25 glomeruli per animal was used for assessment.
Immunogold electron microscopy
Snap-frozen kidney sections (10 μm) were fixed in 10% formaldehyde for 30 minutes and permeabilized in 0.1% Tween 20 in TBS (0.05 M Tris, 0.9% NaCl, pH 8.2) for 1 hour. The sections were incubated in colloidal gold conjugated goat anti-mouse IgM (British Biocell International, Madison, WI) at 1:20 dilution at 4°C overnight. After washing in TBS for 30 min, the sections were fixed in 1% glutaraldehyde for 10 min, dehydrated in a graded series of ethanol, embedded in Epon, thin-sectioned, and stained with 7.7% uranyl acetate in water and lead citrate solution (2.66% lead nitrate, 3.52% sodium citrate in CO2-free doubledistilled water, pH 12) for transmission electron microscopy.
Murine glomerular mesangial cell culture and flow cytometry
Immortalized murine glomerular mesangial cells (MES-13 cells, from ATCC, Manassas, VA), primary culture of mesangial cells from C57BL/6 mice, and immortalized murine pancreatic endothelial cells (MS-1, from ATCC) were used for flow cytometric analysis.
Primary cultures of mesangial cells were obtained from wild-type two month old C57BL/6 mice as previously described. 32, 33 Kidneys were removed under aseptic technique and cortical tissue was forced through 200 grade mesh. Unencapsulated glomeruli were collected by centrifugation and digested with type I collagenase (Sigma-Aldrich) at 37°C. The glomerular suspension was plated in RPMI 1640 media with 17% FBS, 0.1 Unit/mL insulin (Gibco), and Penicillin-Streptomycin (Gibco) and allowed to grow at 37°C in 5% CO 2 in air.
Characterization of primary mesangial cells demonstrated typical stellate morphology, positive smooth muscle actin staining (Santa Cruz), but were negative for synaptopodin (Sigma) and negative for CD31 (an endothelial cell marker, BioLegend).
Mesangial cells were incubated with 10% wild-type mouse serum in PBS, purified IgM, or vehicle control (PBS) for 30 minutes at 37° C. Cells were washed with PBS and then stained with PE-conjugated rat antibody against mouse IgM, isotype control (PE-conjugated rat IgG isotype control) (Novus, Littleton, CO) or Cy5-conjugated donkey antibody to mouse IgG (Jackson ImmunoResearch). Flow cytometric analysis was performed on a FACS Calibur machine (BD Biosciences, San Jose, CA) and analyzed by CellQuest Pro software (BD Biosciences).
IgM purification and intravenous injection
IgM antibody was purified from wild-type mouse serum. Large-scale purification was performed using a HiTrap Protein G column to remove IgG (Amersham Biosciences, Piscataway, NJ). Proteins were precipitated with polyethylene glycol (Sigma) and the product was run over a size exclusion column to isolate the IgM fractions. The purity of the isolated IgM was established by Coomassie staining and Western blot analysis. The IgM was biotinylated using a EZ-link Sulfo-NHS Biotinylation Kit (ThermoScientific) according to the manufacturer's instructions, and binding of the biotinylated IgM to mesangial cells was confirmed by flow cytometry. Monoclonal natural IgM hybridomas were generated from the B cells of C57BL/6 mice as previously described. 34 Mice were injected with 1 mg of purified polyclonal IgM or 100 μg of the IgM monoclonal antibodies intravenously by tail vein (N=3 for each antibody preparation). For mice injected with polyclonal IgM, urine and serum samples were collected at baseline and on days 1, 2, and 3 following injection. Kidney tissue was obtained on days 1 and 3. Mice injected with the IgM monoclonal antibodies were sacrificed after 24 hours and the kidney tissue was analyzed.
Statistical Analysis
Statistical analysis between treatment groups was assessed by unpaired t test or by ANOVA for multiple groups using GraphPad Prism software (La Jolla, CA). A P value less than 0.05 was considered significant. 
